Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis

DSpace/Manakin Repository

Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis

Citable link to this page

 

 
Title: Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Author: Montesi, Sydney B; Mathai, Susan K; Brenner, Laura N; Gorshkova, Irina A; Berdyshev, Evgeny V; Tager, Andrew M; Shea, Barry S

Note: Order does not necessarily reflect citation order of authors.

Citation: Montesi, Sydney B, Susan K Mathai, Laura N Brenner, Irina A Gorshkova, Evgeny V Berdyshev, Andrew M Tager, and Barry S Shea. 2014. “Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis.” BMC Pulmonary Medicine 14 (1): 5. doi:10.1186/1471-2466-14-5. http://dx.doi.org/10.1186/1471-2466-14-5.
Full Text & Related Files:
Abstract: Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective medical therapies. Recent research has focused on identifying the biological processes essential to the development and progression of fibrosis, and on the mediators driving these processes. Lysophosphatidic acid (LPA), a biologically active lysophospholipid, is one such mediator. LPA has been found to be elevated in bronchoalveolar lavage (BAL) fluid of IPF patients, and through interaction with its cell surface receptors, it has been shown to drive multiple biological processes implicated in the development of IPF. Accordingly, the first clinical trial of an LPA receptor antagonist in IPF has recently been initiated. In addition to being a therapeutic target, LPA also has potential to be a biomarker for IPF. There is increasing interest in exhaled breath condensate (EBC) analysis as a non-invasive method for biomarker detection in lung diseases, but to what extent LPA is present in EBC is not known. Methods: In this study, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to assess for the presence of LPA in the EBC and plasma from 11 IPF subjects and 11 controls. Results: A total of 9 different LPA species were detectable in EBC. Of these, docosatetraenoyl (22:4) LPA was significantly elevated in the EBC of IPF subjects when compared to controls (9.18 pM vs. 0.34 pM; p = 0.001). A total of 13 different LPA species were detectable in the plasma, but in contrast to the EBC, there were no statistically significant differences in plasma LPA species between IPF subjects and controls. Conclusions: These results demonstrate that multiple LPA species are detectable in EBC, and that 22:4 LPA levels are elevated in the EBC of IPF patients. Further research is needed to determine the significance of this elevation of 22:4 LPA in IPF EBC, as well as its potential to serve as a biomarker for disease severity and/or progression.
Published Version: doi:10.1186/1471-2466-14-5
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906883/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879673
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters